Patent 11866506 was granted and assigned to Mellitus (company) on January, 2024 by the United States Patent and Trademark Office.
Anti-CD59 and anti-glycated CD59 antibodies are disclosed. Assays, diagnostics, kits, and assay components including such antibodies are provided. Methods for the assessment of diabetes-related indications are included as well as inhibitors of CD59 glycation and methods of evaluating such inhibitors.